• Medicus Pharma received written FDA feedback supporting its optimized Phase 2 Teverelix study in acute urinary retention.
• Advarra, the central IRB, cleared the ANT-2111-02 protocol with modifications through June 18, 2027.
• The redesigned trial targets about 126 patients versus roughly 390 previously planned, aiming to speed dose and route selection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.